TBPH
Theravance Biopharma Inc
NASDAQ: TBPH · HEALTHCARE · BIOTECHNOLOGY
$16.52
-0.49% today
Updated 2026-06-05
Market cap
$908.88M
P/E ratio
7.91
P/S ratio
8.28x
EPS (TTM)
$2.23
Dividend yield
—
52W range
$11 – $21
Volume
0.4M
Theravance Biopharma Inc (TBPH) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$16.52
12-Month target
$15.29
2030 Target
$21.22
Intrinsic (DCF)
$59.74
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 8.38% (capped 20%) · P/E: 7.91x (capped 25x) · Margin: 104.30%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.